0001564590-19-039777.txt : 20191104 0001564590-19-039777.hdr.sgml : 20191104 20191104160539 ACCESSION NUMBER: 0001564590-19-039777 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20191104 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 191189779 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 myok-8k_20191104.htm 8-K myok-8k_20191104.htm
MyoKardia Inc false 0001552451 0001552451 2019-11-04 2019-11-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2019

 

MYOKARDIA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-37609

44-5500552

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

333 Allerton Ave.

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 741-0900

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

MYOK

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2019, MyoKardia, Inc. announced its financial results for the third quarter ended September 30, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release issued by MyoKardia, Inc. on November 4, 2019, furnished herewith

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 4, 2019

 

 

MyoKardia, Inc.

 

 

 

 

 

 

By:

 

/s/ Taylor Harris

 

 

 

 

 

Taylor Harris

 

 

 

 

 

Chief Financial Officer (principal financial officer)

 

 

 EX-99.1 2 myok-ex991_15.htm EX-99.1 myok-ex991_15.htm

Exhibit 99.1

News Release

 

 

MyoKardia Reports Third Quarter 2019 Financial Results

 

 

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019.

 

“As we look across the milestones recently achieved and those just ahead, we see steady progress on our near- and long-term corporate objectives. We are forging a position of disease-area leadership in the improved care of hypertrophic cardiomyopathy, while applying all that we are learning from those efforts to tackle additional targeted populations with diseases caused by diastolic or systolic dysfunction,” said Tassos Gianakakos, MyoKardia’s Chief Executive Officer. “Before year-end, we will be reporting 48-week data from our PIONEER-OLE study in obstructive HCM, as well as data from our Phase 2 MAVERICK-HCM study in patients with non-obstructive hypertrophic cardiomyopathy. Our momentum will continue into next year, with additional data and program progress planned across our portfolio for the first half of 2020, including the topline readout from our pivotal Phase 3 EXPLORER-HCM trial of mavacamten in obstructive HCM and the advancement of MYK-491 into a targeted genetic cardiomyopathy population.”  

 

Recent Clinical Program Highlights

 

Mavacamten for Obstructive Hypertrophic Cardiomyopathy

 

 

•

Completed Enrollment of 251 Patients in the Phase 3 EXPLORER-HCM Trial: Enrollment in the pivotal Phase 3 EXPLORER-HCM registrational clinical study of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) completed in July of 2019. MyoKardia anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020.

 

 

•

Presented 36-week Data from PIONEER-OLE Study of Mavacamten: At the European Society of Cardiology Congress 2019, Dr. Andrew Wang of Duke University presented 36-week data from the PIONEER open-label extension study of twelve patients with obstructive HCM. Mavacamten treatment has resulted in durable reductions in obstruction of the left ventricular outflow tract (LVOT) while maintaining left ventricular ejection fraction (LVEF) at or above normal levels. Sustained improvements in multiple biomarkers of cardiac stress and diastolic filling pressures were also observed.

 

 

•

Formed Partnership with the Cleveland Clinic for Septal Reduction Therapy (SRT) Study: MyoKardia and the Cleveland Clinic will begin a randomized, double-blind study of symptomatic, obstructive HCM patients referred for septal reduction therapy (SRT) starting in the first half of 2020. The study will be conducted at leading HCM centers that regularly perform surgical myectomy or alcohol septal ablation procedures, with support from the established referral networks at those centers.

 

MYK-491 for Dilated Cardiomyopathy

 

 

•

Reported Positive Data from Phase 2a Study of MYK-491: An interim analysis of 26 patients with stable heart failure due to left ventricular systolic dysfunction in the ongoing Phase 2a clinical trial showed that MYK-491 demonstrated improvement in systolic function, including stroke volume increases of greater than 10 percent relative to baseline on a placebo-adjusted basis, without impacting diastolic function. Given the favorable safety profile observed to date, the Phase 2a study has been extended to evaluate higher exposures of MYK-491.

 

Driven by the Heart

 

333 Allerton Avenue, South San Francisco, CA 94080 / +1 650 351 4705 / myokardia.com

 

 

 

•

Announced Plans to Advance MYK-491 into a Phase 2 Study in Genetic Dilated Cardiomyopathy (DCM) Population: MyoKardia plans to advance MYK-491 into a Phase 2 clinical trial in DCM patients with certain genetic mutations of the cardiac sarcomere in the first half of 2020. Genetic mutations of the sarcomere impair the ability of the heart muscle proteins to function effectively, leading to progressive worsening of function. Genetic abnormalities contributing to DCM are estimated to be present in about 30-40% of DCM patients, corresponding to an estimated prevalence of 250,000 to 500,000 people in the U.S.

 

MYK-224 for HCM

 

 

•

Began Dosing Healthy Subjects in a Phase 1 Clinical Trial of MYK-224: The Phase 1 clinical trial of MYK-224 is intended to evaluate safety, tolerability and pharmacokinetics. Pharmacodynamic effects on cardiac function and dimensions will also be assessed. MYK-224 joins MyoKardia’s growing portfolio of therapeutic candidates targeting proteins of the heart muscle to address cardiovascular diseases of excessive contraction, inadequate contraction, or impaired relaxation. Topline results are expected in mid-2020.   

 

Recent Corporate Highlights

 

 

•

Launched 2nd Annual MyoSeeds™ Research Grant Program Funding Cycle: MyoKardia received more than 60 proposals for its MyoSeeds initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision treatment for heart disease. Through this program, MyoKardia will fund up to four awards, with a total investment of up to $1 million in funding over 2019-2020. Award recipients will be announced in the first quarter of 2020.

 

Third Quarter 2019 Financial Results

 

 

•

Cash Position: Cash, cash equivalents and investments (short-term and long-term) as of September 30, 2019 were $480.4 million, compared to $394.8 million as of December 31, 2018.  The change in MyoKardia’s cash position was primarily attributable to the net proceeds from our March 2019 offering of $271.2 million, offset by our year-to-date losses of $217.4 million, which includes a $80.0 million payment to Sanofi for the purchase of mavacamten and MYK-224 royalty rights.

 

 

•

Revenues: MyoKardia did not record revenue from the Sanofi collaboration during the third quarter and nine months ended September 30, 2019. For the three and nine months ended September 30, 2018, collaboration and license revenue totaled $9.2 million and $21.2 million, respectively. MyoKardia fulfilled its research and development obligations under the collaboration agreement during the year ended December 31, 2018, and no further revenue will be recorded under the agreement.

 

 

•

R&D Expenses: Research and development expenses were $47.4 million for the third quarter of 2019, up from $15.9 million for the same period in 2018. R&D expenses in the first nine months of 2019 were $101.3 million, up from $49.7 million for the same period in 2018. The increase in R&D expenses was primarily driven by clinical trial activity for mavacamten, MYK-491, and MYK-224, a decrease in Sanofi reimbursement credits, increases in contract research, chemistry and biology expenses related to discovery and pre-clinical programs, increases in contract manufacturing expenses, and increases in headcount and stock-based compensation expense.
 

 

•

SG&A Expenses: Selling, general and administrative expenses were $17.7 million for the three months ended September 30, 2019, compared to $11.0 million for the same period in 2018. For the first nine months of 2019, SG&A expenses were $45.2 million compared to $27.2 million in the same period in 2018. The increase in SG&A expenses was primarily attributable to an

 

 

 

increase in headcount, stock-based compensation expense, professional service and consulting expenses, and office and facilities-related expenses.

 

 

•

Net Loss: Net loss for the third quarter of 2019 was $141.8 million ($3.07 per share), of which $80.0 million ($1.73 per share) was related to the non-recurring repurchase from Sanofi of royalty rights to mavacamten and MYK-224, and $61.8 million ($1.34 per share) was related to loss from operations, compared to a net loss of $15.8 million ($0.39 per share) for the third quarter of 2018. For the nine months ended September 30, 2019, net loss was $217.4 million ($4.91 per share), of which $80.0 million ($1.81 per share) was related to the repurchase of royalty rights and $137.4 million ($3.10 per share) was related to loss from operations, compared to $52.0 million ($1.38 per share) during the same period of 2018.

 

Based on the company’s current balance of cash and investments, MyoKardia estimates having sufficient funds to execute on current operating plans into the second half of 2021.  

 

In lieu of conducting a third quarter financial results call, MyoKardia management will host a conference call on Monday, November 11, 2019 at 8:30 a.m. ET/5:30 a.m. PT to discuss PIONEER-OLE 48-week data being presented at the upcoming American Heart Association Scientific Sessions 2019.  Investors and analysts are invited to participate by phone by calling 844-494-0913 in the U.S. and Canada or 508-637-5584 internationally and using the conference ID 3177984 or by webcast. The webcast can be accessed from the investor section of the MyoKardia website at www.myokardia.com.

 

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the muscle proteins of the heart that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia applies a precision medicine approach to develop its therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. MyoKardia has discovered a pipeline of product candidates directed at diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly 461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM); MYK-491 in Phase 2 for patients with stable heart failure; and MYK-224, in Phase 1 development for HCM.

 

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

 

Forward-Looking Statements

 

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten, MYK-491 and MYK-224, the availability of the 48-week data from PIONEER-OLE and data from EXPLORER-HCM, as well as from the Phase 2 MAVERICK-HCM study in patients with non-obstructive HCM, the Company’s expectation with respect to release of data from these studies, the Company’s ability to advance MYK-491 into a Phase 2 study in patients with genetic DCM and the commencement of a study of mavacamten in symptomatic, obstructive HCM patients referred for SRT, and the timing of these events and the availability of data from the Phase 1 study of MYK-224 in healthy subjects, as well as the Company’s projected cash runway, reflect our current views about our plans, intentions, expectations,

 

 

strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements ad will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contacts

Michelle Corral

Senior Director, Corporate Communications and Investor Relations

MyoKardia, Inc.

650-351-4690

ir@myokardia.com  

 

Hannah Deresiewicz (investors)

Stern Investor Relations, Inc.

212-362-1200

hannah.dereseiwicz@sternir.com

 

Julie Normart (Media)

W2O

628-213-3754

jnormart@w2ogroup.com


 

 

MYOKARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

 

 

September 30,

2019

 

 

December 31,

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

235,159

 

 

$

246,122

 

Short-term investments

 

 

181,932

 

 

 

68,564

 

Prepaid expenses and other current assets

 

 

7,598

 

 

 

4,760

 

Total current assets

 

 

424,689

 

 

 

319,446

 

Property and equipment, net

 

 

7,148

 

 

 

5,138

 

Operating lease right-of-use assets

 

 

1,028

 

 

 

—

 

Long-term investments

 

 

63,328

 

 

 

80,148

 

Restricted cash and other

 

 

2,404

 

 

 

2,521

 

Total assets

 

$

498,597

 

 

$

407,253

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

 

6,528

 

 

$

2,946

 

Accrued liabilities

 

 

36,507

 

 

 

20,758

 

Prepayment from collaboration partner

 

 

—

 

 

 

12,973

 

Operating lease liabilities - current

 

 

1,050

 

 

 

—

 

Total current liabilities

 

 

44,085

 

 

 

36,677

 

Other long-term liabilities

 

 

2,159

 

 

 

9

 

Total liabilities

 

 

46,244

 

 

 

36,686

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none

   issued and outstanding

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value, 150,000,000 shares authorized

   at September 30, 2019 and December 31, 2018; 46,218,925 and

   40,288,949 shares issued and outstanding at September 30, 2019

   and December 31, 2018, respectively

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

871,894

 

 

 

573,183

 

Accumulated other comprehensive income (loss)

 

 

453

 

 

 

(67

)

Accumulated deficit

 

 

(419,999

)

 

 

(202,553

)

Total stockholders’ equity

 

 

452,353

 

 

 

370,567

 

Total liabilities and stockholders’ equity

 

$

498,597

 

 

$

407,253

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MYOKARDIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Collaboration and license revenue

 

$

—

 

 

$

9,188

 

 

$

—

 

 

$

21,158

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Repurchase of royalty rights

 

 

80,000

 

 

 

—

 

 

 

80,000

 

 

 

—

 

Research and development

 

 

47,372

 

 

 

15,910

 

 

 

101,270

 

 

 

49,746

 

Selling, general and administrative

 

 

17,746

 

 

 

10,957

 

 

 

45,153

 

 

 

27,182

 

Total operating expenses

 

 

145,118

 

 

 

26,867

 

 

 

226,423

 

 

 

76,928

 

Loss from operations

 

 

(145,118

)

 

 

(17,679

)

 

 

(226,423

)

 

 

(55,770

)

Interest and other income, net

 

 

3,332

 

 

 

1,890

 

 

 

8,775

 

 

 

3,748

 

Loss before income taxes

 

 

(141,786

)

 

 

(15,789

)

 

 

(217,648

)

 

 

(52,022

)

Income tax expense (benefit)

 

 

16

 

 

 

—

 

 

 

(202

)

 

 

—

 

Net loss

 

 

(141,802

)

 

 

(15,789

)

 

 

(217,446

)

 

 

(52,022

)

Other comprehensive (loss) income, net of tax effect of

   $17, $0, $(202) and $0, respectively

 

 

(44

)

 

 

37

 

 

 

520

 

 

 

(30

)

Comprehensive loss

 

$

(141,846

)

 

$

(15,752

)

 

$

(216,926

)

 

$

(52,052

)

Net loss per share, basic and diluted

 

$

(3.07

)

 

$

(0.39

)

 

$

(4.91

)

 

$

(1.38

)

Weighted average number of shares used to compute net loss per share, basic and diluted

 

 

46,133,068

 

 

 

40,116,644

 

 

 

44,255,657

 

 

 

37,765,631

 

 

 

 GRAPHIC 3 g0pix2mv5j21000001.jpg GRAPHIC begin 644 g0pix2mv5j21000001.jpg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myok-20191104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 myok-20191104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 myok-20191104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports myok-8k_20191104.htm myok-20191104.xsd myok-20191104_lab.xml myok-20191104_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "myok-8k_20191104.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "myok-8k_20191104.htm" ] }, "labelLink": { "local": [ "myok-20191104_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "myok-20191104_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "myok-20191104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "myok", "nsuri": "http://www.myokardia.com/20191104", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "myok-8k_20191104.htm", "contextRef": "C_0001552451_20191104_20191104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "myok-8k_20191104.htm", "contextRef": "C_0001552451_20191104_20191104", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20191104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 11 myok-8k_20191104_htm.xml IDEA: XBRL DOCUMENT 0001552451 2019-11-04 2019-11-04 MyoKardia Inc false 0001552451 8-K 2019-11-04 DE 001-37609 44-5500552 333 Allerton Ave. South San Francisco CA 94080 (650) 741-0900 false false false false Common Stock MYOK NASDAQ false XML 12 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Document And Entity Information
Nov. 04, 2019
Cover [Abstract]  
Entity Registrant Name MyoKardia Inc
Amendment Flag false
Entity Central Index Key 0001552451
Document Type 8-K
Document Period End Date Nov. 04, 2019
Entity Incorporation State Country Code DE
Entity File Number 001-37609
Entity Tax Identification Number 44-5500552
Entity Address, Address Line One 333 Allerton Ave.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 741-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol MYOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

ZIP 15 0001564590-19-039777-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-039777-xbrl.zip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end XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }